Market data including bonds and fuel prices
The miner has instituted projects to decrease the social wage deficit, ranging from education to roads
President laments that scarcely a day passes without reports about men attacking, violating and killing women
Chair Siboniso Duma says province may well support Ramaphosa for a second term
Antitrust suit would be the US justice department’s second case against Google
The Trump-era tariffs on imported metals have been eased for some other countries
In the wake of SAA’s near-demise Comair’s market share crept up to 35%-40% by the time it too collapsed
Ahmad Abouammo was found guilty of turning over personal information of platform users who’d criticised the Saudi royal family
Failure to win on Saturday would put coach Ian Foster and captain under pressure in terms of their future with the team
Nicholas Yell trades SUV for saddle and makes his way from Bot River to Merweville and on to Kruisrivier
Technology that allows alteration of genes in a human embryo has been used for the first time in the US, according to Oregon Health and Science University (OHSU) in Portland, which carried out the research.
The OHSU research is believed to have broken new ground both in the number of embryos experimented upon and by demonstrating it is possible to safely and efficiently correct defective genes that cause inherited diseases, according to Technology Review, which first reported the news.
None of the embryos was allowed to develop for more than a few days, according to the report.
Some countries have signed a convention prohibiting the practice on concern that it could be used to create so-called designer babies.
Results of the peer-reviewed study are expected to be published soon in a scientific journal, OHSU spokesman Eric Robinson said.
The research, led by Shoukhrat Mitalipov, head of OHSU’s Center for Embryonic Cell and Gene Therapy, involves a technology known as CRISPR that has ...
A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.
Already subscribed? Simply sign in below.
Questions or problems? Email email@example.com or call 0860 52 52 00. Got a subscription voucher? Redeem it now
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.